Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China's BeiGene Starts Combination Trial for Two Novel Cancer Drugs

publication date: Jul 6, 2016
BeiGene, a Beijing novel cancer biopharma, has dosed the first patient in a Phase I trial that combines a targeted BTK inhibitor with a PD-1 immuno-oncology antibody. BeiGene developed both molecules in-house. The trial, which will enroll 25 patients with B-cell lymphoid malignancies, will be conducted in Australia. BeiGene has another combination trial already underway. The earlier trial pairs the PD-1 immuno-oncology drug with a PARP inhibitor. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital